C1QTNF9 and myocardial infarction: Through intravenous administration of CTRP9, prior to promoting ischemia and after promoting myocardial perfusion in mice, this study confirmed a decrease in the extension of the injury caused by myocardial infarction in the animals of the study groups, through AMPK activation via the AdipoR1 receptor in the cardiac myocytes resulting from the endocrine action of CTRP9.